Skip to content

Melatonin in the treatment of the ICU sleep deprivation: a single-center, prospective, randomized, double-blind, placebo-controlled, parallel study

Melatonin in the treatment of the ICU sleep deprivation: a single-center, prospective, randomized, double-blind, placebo-controlled, parallel study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004319
Enrollment
Unknown
Registered
2014-01-14
Start date
2014-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep deprivation in ICU patients

Interventions

placebo group:oral placebo

Sponsors

Beijing Fuxing Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and more; 2. Glasgow Coma Scale(GCS-M) =10; 3. Sedation had been discontinued for a minimum of 36 hrs for propofol and alfentanil and 48 hrs for lorazep am, morphine and midazolam; 4. Estimated length of mechanical ventilation at ICU admission = 3 days; 5. patients were clinically and biologically stable, and pass the weaning screening[39], and therefore ready to be weaned from mechanical vatilation; 6. undergo the tracheotomy.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women; 2. Preadmission treatment of sleep disturbances; 3. A history of convulsions, psychiatric or neurological disease, sleep apnoea, deafness and blindness; Alcohol consumption of greater than or equal to 50 unit per week or drug use; 4. Liver insufficiency (child-pugh C); 5. Renal insufficiency; Severe heart failure (New York Heart Association classification III/IV); 6. Intestinal obstruction, ileus, gastroparesis or other conditions likely to affect enteral absorption of melatonin; 7. Useing drugs which might alter melatonin secretion and decrease plasma levels of melatonin, such as benzo -diazepines, NSAIDs, Corticosteroids, beta-blockers, haloperidol, amiodarone; 8. known allergy to melatonin; 9. Readmitted to ICU after randomization to the study; 10. Enrolled in another trial.

Design outcomes

Primary

MeasureTime frame
Objective sleep quality;

Secondary

MeasureTime frame
subjective sleep quality;anxiety level;Delirum-free days in 28 days;Ventilation-free days in 28 days;Antibiotic -free days in 28 days;ICU/hospital length of stay;

Contacts

Public ContactXi Xiuming

Beijing Fuxing Hospital, Capital Medical University

xxm_fxyy@sina.cn+86 13801244610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 7, 2026